Log In
BCIQ
Print this Print this
 

OT329

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionCombination of fluticasone propionate and salmeterol xinafoate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase I
Standard IndicationAsthma
Indication DetailsTreat asthma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today